TY - JOUR
T1 - Treatment with ixekizumab following secukinumab failure in patients with psoriatic arthritis
T2 - Real-life experience from a resistant population
AU - Berman, Julia
AU - Furer, Victoria
AU - Berman, Mark
AU - Isakov, Ofer
AU - Zisman, Devy
AU - Haddad, Amir
AU - Elkayam, Ori
N1 - Publisher Copyright:
© 2021 Berman et al.
PY - 2021
Y1 - 2021
N2 - Objective: To assess the clinical response to ixekizumab following secukinumab failure in patients with psoriatic arthritis. Methods: A retrospective multi-center observational study included psoriatic arthritis (PsA) patients with a history of treatment with secukinumab, further treated with ixekizumab. Primary endpoint was primary response to treatment (drug survival > 6 months); secondary endpoints were changes in disease activity indices from initiation of ixekizumab to 6 and 12 months later and overall drug survival. Results: Of 23 PsA patients, 86% (n = 20) received more than two TNF inhibitors (TNFi). Median secukinumab treatment time was 15 months (IQR 10–21.5 months). Subsequently, 19 patients (83%) had a primary response to ixekizumab. Overall treatment duration during follow-up period for primary responders was 14 months (IQR 10–20.5). Reasons for ixekizumab cessation were worsening psoriasis (27%), peripheral arthritis (27%), both (47%), worsening of axial disease (13%), and adverse events (6%). Articular disease indices including Disease Activity Index for Psoriatic Arthritis (DAPSA), tender joints count (TJC) and Simplified Disease Activity Index (SDAI) were significantly lower at 6 and 12 months (DAPSA 1.5–2 levels reduction; p = 0.018 and 1–1.5 levels reduction; p = 0.031, respectively; TJC −2.16 [−4.0, −0.3]; p = 0.025 and −1.69 [−3.09, −0.28]; p = 0.022, respectively; SDAI −10.13 [−16.4, −3.8], p = 0.003 and −12.2 [−17.1, −7.2], p = 0.0002, respectively). PASI75 at 6 and 12 months was achieved by 63% and 57%, respectively, and PASI100 at 6 and 12 months by 31% and 21%, respectively. Conclusion: Patients with resistant PsA, including inadequate response to secukinumab, demonstrated a good response to ixekizumab, albeit limited on time. Within class switch from secukinumab to ixekizumab may be a plausible therapeutic option in PsA patients following secukinumab failure.
AB - Objective: To assess the clinical response to ixekizumab following secukinumab failure in patients with psoriatic arthritis. Methods: A retrospective multi-center observational study included psoriatic arthritis (PsA) patients with a history of treatment with secukinumab, further treated with ixekizumab. Primary endpoint was primary response to treatment (drug survival > 6 months); secondary endpoints were changes in disease activity indices from initiation of ixekizumab to 6 and 12 months later and overall drug survival. Results: Of 23 PsA patients, 86% (n = 20) received more than two TNF inhibitors (TNFi). Median secukinumab treatment time was 15 months (IQR 10–21.5 months). Subsequently, 19 patients (83%) had a primary response to ixekizumab. Overall treatment duration during follow-up period for primary responders was 14 months (IQR 10–20.5). Reasons for ixekizumab cessation were worsening psoriasis (27%), peripheral arthritis (27%), both (47%), worsening of axial disease (13%), and adverse events (6%). Articular disease indices including Disease Activity Index for Psoriatic Arthritis (DAPSA), tender joints count (TJC) and Simplified Disease Activity Index (SDAI) were significantly lower at 6 and 12 months (DAPSA 1.5–2 levels reduction; p = 0.018 and 1–1.5 levels reduction; p = 0.031, respectively; TJC −2.16 [−4.0, −0.3]; p = 0.025 and −1.69 [−3.09, −0.28]; p = 0.022, respectively; SDAI −10.13 [−16.4, −3.8], p = 0.003 and −12.2 [−17.1, −7.2], p = 0.0002, respectively). PASI75 at 6 and 12 months was achieved by 63% and 57%, respectively, and PASI100 at 6 and 12 months by 31% and 21%, respectively. Conclusion: Patients with resistant PsA, including inadequate response to secukinumab, demonstrated a good response to ixekizumab, albeit limited on time. Within class switch from secukinumab to ixekizumab may be a plausible therapeutic option in PsA patients following secukinumab failure.
KW - Antibodies
KW - Arthritis
KW - Duration of therapy
KW - Humanized
KW - Ixekizumab
KW - Monoclonal
KW - Psoriasis
KW - Psoriatic
KW - Secukinumab
UR - http://www.scopus.com/inward/record.url?scp=85119686132&partnerID=8YFLogxK
U2 - 10.2147/BTT.S326792
DO - 10.2147/BTT.S326792
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34819720
AN - SCOPUS:85119686132
SN - 1177-5475
VL - 15
SP - 463
EP - 470
JO - Biologics: Targets and Therapy
JF - Biologics: Targets and Therapy
ER -